FGF23 and hip fracture: Our data suggest that either FGF-23 or IL-15RA or both should be assessed as potential biomarkers to make accurate clinical decisions regarding risk of postoperative AKI and to evaluate the risk of mortality and complications in frail hip fracture patients.